Table 2. Non-significant meta-analysis results of the association between mTOR polymorphisms and cancer risk.

	No.of studies	OR(95%CI)	P	I2(%)	Phet	Model
rs2536
Total	7(6093/6442)
CC vs.TT		1.11(0.75,1.64)	0.613	0	0.921	Fixed-effects model
TC vs.TT		1.01(0.86,1.18)	0.902	62.4	0.014	Random-effects model
CC vs.TC		1.06(0.71,1.59)	0.764	0	0.667	Fixed-effects model
Excluding Li's study	6(5089/5391)
CC vs.TT		1.16(0.75, 1.79)	0.501	0	0.884	Fixed-effects model
TC vs.TT		0.97(0.87,1.07)	0.504	20.4	0.28	Fixed-effects model
CC vs.TC		1.20(0.77,1.87)	0.422	0	0.77	Fixed-effects model
CC vs.CT/TT		1.17(0.76, 1.80)	0.485	0	0.869	Fixed-effects model
Genitourinary cancers	3(2380/2519)
CC vs.TT		1.01(0.52, 1.98)	0.966	0	0.901	Fixed-effects model
TC vs.TT		1.00(0.67, 1.49)	0.991	84.8	0.001	Random-effects model
CC vs.TC		0.93(0.47, 1.82)	0.824	0	0.472	Fixed-effects model
Digestive system cancers	3(3296/3369)
CC vs.TT		1.03(0.61, 1.74)	0.927	0	0.905	Fixed-effects model
CT vs.TT		1.06(0.93, 1.21)	0.378	0	0.677	Fixed-effects model
CC vs.CT		0.98(0.57, 1.68)	0.94	0	0.974	Fixed-effects model
CC vs.CT/TT		1.02(0.60, 1.72)	0.947	0	0.918	Fixed-effects model
rs3806317
Total	2(2006/2054)
GG vs.AA		0.79(0.50, 1.26)	0.326	0	0.358	Fixed-effects model
GA vs.AA		1.07(0.82, 1.40)	0.61	70.8	0.064	Random-effects model
GG vs.GA		0.73(0.45, 1.17)	0.187	0	0.73	Fixed-effects model
rs1064261
Total	2(1599/1790)
CC vs.TT		0.90(0.38, 2.15)	0.82	0	0.556	Fixed-effects model
TC vs.TT		1.14(0.95, 1.37)	0.171	8.7	0.295	Fixed-effects model
CC vs.TC		0.82(0.34, 1.99)	0.665	0	0.417	Fixed-effects model
TC vs.CC/TT		1.14(0.95, 1.37)	0.168	11.9	0.287	Fixed-effects model